Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs Sanofi SA (SNY) Price & Performance

Global E Online LtdTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs Sanofi SA — how do they compare? Global E Online Ltd trades at $46.52 (market cap $6.87B), while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 15.2× Global E Online Ltd's market cap, and Sanofi SA pays a 5.55% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.

GLBESNY
Market Cap
$6.87B$104.30B
Sector
TechnologyHealth
52-Week High
$42.32$52.34
52-Week Low
$27.54$41.33
Enterprise Value
$6.34B$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.

GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.

Sanofi SA

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY